Sponsored by:

Crown Bioscience

Beyond Exposure: Integrating PK/PD for Translational Predictive Power

Watch Now
Date:
May 19, 2026
Time (ET):
11:00 AM
Duration (min):
30
Register Now
Crown Bioscience

Join us on May 19 to master PK/PD integration and learn how to transform exposure data into accurate predictions of clinical success.

Relying on exposure data alone is a leading cause of translational failure. To truly predict clinical outcomes, you must bridge the gap between drug concentration and biological effect. This webinar provides a masterclass in integrating pharmacokinetics (PK) with pharmacodynamics (PD) to transform raw data into a roadmap for candidate success.

Featuring Insights from

Rekha Pal

,

PhD

Crown Bioscience
Senior Director, Scientific Engagement

Dr. Rekha Pal is a highly accomplished cancer biologist specializing in immuno-oncology, translational research, and the tumor microenvironment. With extensive experience across both discovery and clinical development, she has led programs for targeted therapies and immune checkpoint inhibitors, including pivotal work on the molecular targets of thalidomide derivatives like pomalidomide and lenalidomide. Dr. Pal excels at bridging the gap between bench and clinic by developing complex cell-based disease models—such as organoids and primary human cell cultures—and collaborating with computational biologists to correlate genomic signatures with drug interactions for biomarker selection. Her multifaceted expertise at Crown Bioscience encompasses the design of in vitro and in vivo studies, the establishment of clinical protocols for patient sample analysis, and the successful navigation of IRB and IACUC regulatory frameworks to accelerate drug development programs.

Read More

Sponsored by

Crown Bioscience

Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to advancing human health by partnering with biotech and pharmaceutical companies that are at the forefront of drug discovery and development in oncology and immuno-oncology. Providing a range of integrated solutions, including preclinical research services, translational platforms, and clinical trial support. Its offer includes the world’s largest commercially available patient-derived xenograft (PDX) collection and more than 600 tumor organoid models utilizing Hubrecht Organoid Technology, covering 22 cancer indications. Crown Bioscience’s expertise extends across a diverse portfolio of platforms and services that utilize in vivo, in vitro, ex vivo, and in silico methods, along with advanced laboratory services that span the entire drug development timeline. Additionally, it maintains an extensive biobank of liquid and human biospecimens, complete with clinical histories. Operating from 11 facilities in the US, Europe, and APAC—including laboratories accredited by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO)—Crown Bioscience upholds the highest standards of quality and reliability in its research environments.

In Partnership with

Scientist.com

Scientist.com is the world’s largest and first platform built for the intricacies of scientific outsourcing.

We help pharmaceutical and biotechnology organizations discover, engage, manage, and scale relationships with the providers that support every stage of the pipeline—from discovery and preclinical research to clinical development, manufacturing, medical affairs, and commercialization. Through a centralized platform, organizations can access a global network of 6,000+ providers, streamline sourcing and procurement workflows, maintain compliance, manage supplier relationships, and leverage data-driven insights to make faster, more informed decisions.

Today, Scientist.com supports more than 130 life science organizations, including 24 of the world's top 30 pharmaceutical companies, helping teams reduce operational complexity, accelerate timelines, and bring innovations to patients faster. Our mission is to make it possible to cure all human disease by 2050.

Related Content

Related Content